RICHARD PAUL JUNGHANS, MD
Osteopathic Medicine at Washington St, Boston, MA
License number
Massachusetts MD11666
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
Massachusetts 74718
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
Massachusetts 74718
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
800 Washington St, Boston, MA 02111
Phone
(617) 636-5982
Professional information
Antibodies As Chimeric Effector Cell Receptors Against Tumor Antigens
US Patent:
2007003, Feb 8, 2007
Filed:
Oct 16, 2006
Appl. No.:
11/581549
Inventors:
Richard Junghans - Boston MA, US
International Classification:
A61K 39/395, C07H 21/04, C12P 21/06, C12N 5/06, C07K 16/30
US Classification:
424155100, 435069100, 435326000, 435320100, 530388800, 536023500
Abstract:
This invention relates to specific antibodies against ganglioside GD3 called MB3.6 and against protein prostate specific membrane antigen (PSMA) called 3D8, 4D4 and 3E11 when prepared as chimeric molecules with signaling molecules of T cells and other effector cells, and the use thereof in the treatment of cancers expressing these antigens.
Methods And Compositions For Treating Hiv
US Patent:
2013018, Jul 18, 2013
Filed:
Apr 14, 2011
Appl. No.:
13/641245
Inventors:
Richard P. Junghans - Boston MA, US
Nithianandan Selliah - Providence RI, US
Nithianandan Selliah - Providence RI, US
Assignee:
ROGER WILLIAMS MEDICAL CENTER - Providence RI
International Classification:
A61K 35/30
US Classification:
424 9321, 4353201, 435325
Abstract:
The invention features nucleic acid constructs encoding chimeric immune T-cell receptors (CIRs) that are useful for treating HIV in patients. In general, the CIRs contain an extracellular domain which targets HIV or HIV infected cells (e.g., the extracellular domain of CD4), a transmembrane domain, and a cytoplasmic domain for mediating T-cell activation (e.g., CD3 zeta and/or the partial extracellular domain of CD28). The invention also features the use of host cells expressing CIRs in the treatment of HIV.
Antibodies As Chimeric Effector Cell Receptors Against Tumor Antigens
US Patent:
2002013, Sep 19, 2002
Filed:
Dec 10, 2001
Appl. No.:
10/006773
Inventors:
Richard Junghans - Boston MA, US
International Classification:
C07K001/00, C07K014/00, C07K017/00
US Classification:
530/350000
Abstract:
This invention relates to specific antibodies against ganglioside GD3 called MB3.6 and against protein prostate specific membrane antigen (PSMA) called 3D8, 4D4 and 3E11 when prepared as chimeric molecules with signaling molecules of T cells and other effector cells, and the use thereof in the treatment of cancers expressing these antigens.
Generation Of Modified Molecules With Increased Serum Half-Lives
US Patent:
2002014, Oct 3, 2002
Filed:
Aug 17, 1999
Appl. No.:
09/375924
Inventors:
MICHAEL GALLO - SAN JOSE CA, US
RICHARD JUNGHANS - BOSTON MA, US
ORIT FOORD - FOSTER CITY CA, US
RICHARD JUNGHANS - BOSTON MA, US
ORIT FOORD - FOSTER CITY CA, US
International Classification:
C12P021/06, C12P021/04, C12P021/08, C07K016/00
US Classification:
435/069100, 435/069600, 530/387300, 530/388100, 530/388230
Abstract:
In accordance with the present invention, there are provided methods for the extension of serum half-lives of proteinaceous molecules, particularly antibody molecules, and compositions of molecules modified in accordance with the methods of the invention. In accordance with a first aspect of the present invention, there is provided a method of modifying the half-life of an antibody through providing an antibody containing an FcRn binding domain or the genes encoding such antibody and physically linking the antibody or the antibody as encoded to a second FcRn binding domain. In accordance with a second aspect of the present invention, there is provided a molecule that contains at least two distinct FcRn binding moieties.
Chimeric Effector Cell Receptors Against Carcinoembryonic Antigen
US Patent:
2002016, Nov 7, 2002
Filed:
Dec 10, 2001
Appl. No.:
10/006771
Inventors:
Richard Junghans - Boston MA, US
International Classification:
C07K016/46
US Classification:
530/387300, 530/391100
Abstract:
This invention relates to a specific humanized antibody against carcinoembryonic antigen (CEA) called hMN14 when prepared as a chimeric molecule with signaling molecules of T cells and other effector cells, and the use thereof in the treatment of cancers expressing CEA.